Modular Medical, Inc. news
Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product.
The Company has continued to make progress on the testing required for its 510(k) submission to the U.S. Food and Drug Administration ("FDA") of its MODD1 insulin pump product. The Co
Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, the Company`s Chief Executive Officer, will be participating in the following investor conferences:
Piper Sandler 34th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York
Modular Medical Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today provided an update on its insulin pump product.
The Company has successfully completed the majority of the tests and documentation required for its 510(k) submission with the U.S. Food and Drug Administration ("FDA") of its MODD1 insulin pump product. However,
Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the
Modular Medical Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, the Company`s Chief Executive Officer, is scheduled to present at the LD Micro Invitational XII Investor Conference on Wednesday, June 8, 2022 at 3:30 PM PT, at the Four Seasons Hotel in Westlake Village, California.
Mr. Besser will
Modular Medical, Inc., (NASDAQ:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, announced today the pricing of its underwritten public offering of 2,500,000 units at a price to the public of $6.00 per unit, for aggregate gross proceeds of $15 million, prior to deducting underwriting di
Modular Medical, Inc. (the "Company" or "Modular Medical") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its Board of Directors with the appointment of two independent directors, Steven G. Felsher and Philip B. Sheibley.
The Company`s Chief Executive Officer, Lynn O`Conno
Modular Medical, Inc. (the "Company") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced a "reverse split" of its shares of common stock at a ratio of 1-for-3. The Company`s common stock will begin trading on a post-split basis on Monday, November 29, 2021 under the trading symbol "MODDD." The "D" wil
Modular Medical, Inc. (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its executive team with the appointment of Lynn O`Connor Vos as its new Chief Executive Officer.
The company`s founder, industry veteran and renowned diabetes medical innovator, Paul DiPerna, will take on